Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Microbiological profile of infectious keratitis in a reference centre

Search Title by author or title

Session Details

Session Title: Cornea: Medical

Session Date/Time: Tuesday 10/10/2017 | 08:00-10:30

Paper Time: 08:42

Venue: Room 3.6

First Author: : M.Astete CHILE

Co Author(s): :    C. Nazar   F. Vega   L. Fuenzalida              

Abstract Details

Purpose:

To determine the microbiological profile of infectious keratitis and to establish its antibiotics suceptibility

Setting:

Characterization of the microbiological profile of infectious keratitis in patients, who were evaluated, between 2010 and 2017, in Cornea department and Eye Trauma National Centre, Hospital del Salvador, Chile.

Methods:

Retrospective study. Cultures of infectious keratitis were taken and reviewed, between 2010 and 2017 in Hospital del Salvador. Bacterial and fungal cultures were included. Prevalence of each microorganisms were analyzed. Antibiotic sensitivity pattern was studied in bacterial cultures.

Results:

1.134 cultures were obtained, 576 (50.8%) were positive for microorganisms (bacteria or fungi). The most frequent isolated microorganisms was coagulase negative Staphylococcus (CNS) (46.5%), followed by Streptoccocus pneumoniae (13.3%), Staphylococcus aureus (10.7%), Moraxella group (9.8%) and Pseudomonas group (9.5%). 52% were resistant to at least one antibiotic. Tobramycin had the highest resistance (31.1%), followed by Gentamicin (24.6%) and First generation Cephalosporin (15.8%). CNS showed resistance to Tobramycin and Ciprofloxacin in 22.7% and 20.3%, respectively. 28 positive cultures for fungi were found, the most frequent was Fusarium sp. (10 cases), followed by Candida sp. (6 cases).

Conclusions:

Our results were more similar to studies from Europe and North America than those reported from India or Asia. Bacterial resistance to commonly used antibiotics was found, as Tobramycin and Ciprofloxacin. To the best of our knowledge, this study is the largest reported in Latin America.

Financial Disclosure:

NONE

Back to previous